Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07125950) titled 'SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer' on Aug. 6.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Henan Cancer Hospital
Condition:
Advanced Breast Cancer
Intervention:
Drug: SHR2554
Drug: HRS-8080
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 30, 2025
Target Sample Size: 60
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07125950
Published by HT Digital Conte...